Denali Total Stockholder Equity from 2010 to 2024

DNLI Stock  USD 23.70  0.19  0.80%   
Denali Therapeutics' Total Stockholder Equity is increasing with slightly volatile movements from year to year. Total Stockholder Equity is predicted to flatten to about 712.9 M. Total Stockholder Equity is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. View All Fundamentals
 
Total Stockholder Equity  
First Reported
2015-12-31
Previous Quarter
1.4 B
Current Value
1.3 B
Quarterly Volatility
423 M
 
Yuan Drop
 
Covid
Check Denali Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Denali Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 17.6 M, Interest Expense of 8.6 M or Selling General Administrative of 54.3 M, as well as many indicators such as Price To Sales Ratio of 8.47, Dividend Yield of 0.0 or PTB Ratio of 2.17. Denali financial statements analysis is a perfect complement when working with Denali Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Denali Therapeutics Correlation against competitors.
For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.

Latest Denali Therapeutics' Total Stockholder Equity Growth Pattern

Below is the plot of the Total Stockholder Equity of Denali Therapeutics over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Denali Therapeutics' Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Denali Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Total Stockholder Equity10 Years Trend
Slightly volatile
   Total Stockholder Equity   
       Timeline  

Denali Total Stockholder Equity Regression Statistics

Arithmetic Mean431,155,201
Geometric Mean146,806,560
Coefficient Of Variation104.78
Mean Deviation385,818,215
Median394,890,000
Standard Deviation451,759,421
Sample Variance204086.6T
Range1.2B
R-Value0.89
Mean Square Error45421.1T
R-Squared0.79
Slope89,974,954
Total Sum of Squares2857212T

Denali Total Stockholder Equity History

2024712.9 M
2023B
2022B
2021962.3 M
20201.2 B
2019394.9 M
2018546.8 M

About Denali Therapeutics Financial Statements

Investors use fundamental indicators, such as Denali Therapeutics' Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Denali Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Total Stockholder EquityB712.9 M

Currently Active Assets on Macroaxis

When determining whether Denali Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Denali Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Denali Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Denali Therapeutics Stock:
Check out the analysis of Denali Therapeutics Correlation against competitors.
For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.
You can also try the Pattern Recognition module to use different Pattern Recognition models to time the market across multiple global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Denali Therapeutics. If investors know Denali will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Denali Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.76)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.24)
Return On Equity
(0.35)
The market value of Denali Therapeutics is measured differently than its book value, which is the value of Denali that is recorded on the company's balance sheet. Investors also form their own opinion of Denali Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Denali Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Denali Therapeutics' market value can be influenced by many factors that don't directly affect Denali Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Denali Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Denali Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Denali Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.